"One day, you may hear that someone has come up wi
Post# of 36728
Posted On: 10/13/2013 5:09:41 PM
Re: Bigmoneystock #8574
"One day, you may hear that someone has come up with a cure for cancer. Whoever does will make millions of dolllars." 1953
"One day, you may hear that someone has come up with a cure for cancer. Whoever does will make billions of dolllars." 1983
"One day, you may hear that someone has come up with a cure for cancer. Whoever does will make trillions of dolllars." 2013
October 11, 2013
http://www.pharmaceutical-business-review.com/
http://www.pharmaceutical-business-review.com...nol-111013
Edited version
SKTO Announces Third Quarter Report Date. Also Announces Conference Call and Company Milestones.
SK3 Group, Inc. (OTC Pink:SKTO) ("the Company") announced that it plans to release its Quarter III results by month's end.
"Having enhanced our operations and having bolstered our managerial services, the Company is able to report the results of its operations for Quarter III and for the 9 months ending 30 September 2013 earlier than required," said Artemus Mayor, president of SK3 Group, Inc.
"Shortly after reporting our Quarter III fiscal results, we will post on our website http://www.medicalgreens.com a pre-recorded conference call with the officers of the Company to discuss the results and reply to investor questions," added Mr. Mayor.
Chairman of SK3 Group, Inc. Kevin Allyn stated, "The Company had a terrific third quarter."
Mr. Allyn continued, "When the financial results are released, investors will see that we continue in our long-term focus to collect receivables, enhance revenues, and increase cash on hand -- while investing intelligently in the business. We also continue to focus on personnel and acquiring the right business relationships, as we expand the Company's role in the medical marijuana space. We look forward to sharing more details with our investors on each of these points in the near future. Investors will be able to measure our long term progress by how we fare against our milestones."
For the near term, the Company's milestones include increasing revenues, steadily collecting receivables, expanding product offerings, and enhancing the team and its capabilities. Other milestones include cleaning up various corporate matters such as the Company name change, CUSIP change, dividend, audits, and other operational issues.
Previously, the Company announced that its wholly owned subsidiary Medical Greens has obtained the exclusive license for Dharmanol(TM) for the State of California. Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.
Dharmanol(TM) (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
The Company reserves the right to modify or amend its milestones at any time in response to business issues or for any other reason.
About SK3 Group, Inc. SK3 is a healthcare logistics and fulfillmentconsultancy focused on the delivery of alternative care and medicine.With seasoned management, breakthrough technology and best practices,SK3 brings standardization and transparency to this rapidly growingsegment of the alternative care field.
"One day, you may hear that someone has come up with a cure for cancer. Whoever does will make billions of dolllars." 1983
"One day, you may hear that someone has come up with a cure for cancer. Whoever does will make trillions of dolllars." 2013
October 11, 2013
http://www.pharmaceutical-business-review.com/
http://www.pharmaceutical-business-review.com...nol-111013
Edited version
SKTO Announces Third Quarter Report Date. Also Announces Conference Call and Company Milestones.
SK3 Group, Inc. (OTC Pink:SKTO) ("the Company") announced that it plans to release its Quarter III results by month's end.
"Having enhanced our operations and having bolstered our managerial services, the Company is able to report the results of its operations for Quarter III and for the 9 months ending 30 September 2013 earlier than required," said Artemus Mayor, president of SK3 Group, Inc.
"Shortly after reporting our Quarter III fiscal results, we will post on our website http://www.medicalgreens.com a pre-recorded conference call with the officers of the Company to discuss the results and reply to investor questions," added Mr. Mayor.
Chairman of SK3 Group, Inc. Kevin Allyn stated, "The Company had a terrific third quarter."
Mr. Allyn continued, "When the financial results are released, investors will see that we continue in our long-term focus to collect receivables, enhance revenues, and increase cash on hand -- while investing intelligently in the business. We also continue to focus on personnel and acquiring the right business relationships, as we expand the Company's role in the medical marijuana space. We look forward to sharing more details with our investors on each of these points in the near future. Investors will be able to measure our long term progress by how we fare against our milestones."
For the near term, the Company's milestones include increasing revenues, steadily collecting receivables, expanding product offerings, and enhancing the team and its capabilities. Other milestones include cleaning up various corporate matters such as the Company name change, CUSIP change, dividend, audits, and other operational issues.
Previously, the Company announced that its wholly owned subsidiary Medical Greens has obtained the exclusive license for Dharmanol(TM) for the State of California. Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.
Dharmanol(TM) (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
The Company reserves the right to modify or amend its milestones at any time in response to business issues or for any other reason.
About SK3 Group, Inc. SK3 is a healthcare logistics and fulfillmentconsultancy focused on the delivery of alternative care and medicine.With seasoned management, breakthrough technology and best practices,SK3 brings standardization and transparency to this rapidly growingsegment of the alternative care field.
(0)
(0)SK3 Group Inc. (SKTO) Stock Research Links
Scroll down for more posts ▼